Andera Partners
PARIS, I0
$206m in 8 US stocks at the end of 30 June 2026. The top 10 are 100.0% of the money. It changed about 19.7% of the portfolio this quarter.
Value
$206m
Stocks
8
Top 10 share
100.0%
Turnover
19.7%
What changed this quarter
New
Bought for the first time this quarter.
- Avalyn PharmaAVLN14.8% of the fund
Added
Bought more of a stock they already held.
- InventivaIVA6.7% of the fund+100%
Cut
Sold some of their stake.
- EvommuneEVMN9.0% of the fund-27%
Sold out
Sold their entire stake.
None this quarter.
Holdings
- Avalyn PharmaAVLN
- Share
- 14.8%
- Value
- $31m
- Shares
- 929,824
New
- Abivax SAABVX
- Share
- 5.0%
- Value
- $10m
- Shares
- 78,125
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Kestra Medical TechnologiesKMTS | 33.6% | $69m | 2,728,679 | Held |
| Mineralys TherapeuticsMLYS | 20.8% | $43m | 1,591,917 | Held |
| Avalyn PharmaAVLN | 14.8% | $31m | 929,824 | New |
| AgomAb Therapeutics NVAGMB | 9.7% | $20m | 1,538,702 | Held |
| EvommuneEVMN | 9.0% | $18m | 1,391,990 | -27% |
| InventivaIVA | 6.7% | $14m | 3,633,181 | +100% |
| Abivax SAABVX | 5.0% | $10m | 78,125 | Held |
| Nyxoah SANYXH | 0.4% | $882,276 | 522,057 | Held |
Over time and by industry
Value over time
Dec '25
Jun '26
Value is up 16.9% since 31 December 2025.
Where the money is
Health care95.0%
Other5.0%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.